Invivyd, Inc. - Common Stock (NQ:IVVD)

0.9371 -0.0029 (-0.31%)

Streaming Delayed Price Updated: 10:07 AM EDT, Jul 8, 2026 Add to My Watchlist

Price and Volume

Volume	261,564
Open	0.9500
Bid (Size)	0.9250 (1,300)
Ask (Size)	0.9491 (800)
Prev. Close	0.9400
Today's Range	0.9101 - 0.9505
52wk Range	0.4830 - 3.070
Shares Outstanding	109,755,624
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Invivyd Announces Receipt of Twelve Months’ Advanced Notice of Emergency Use Authorization (EUA) Termination for PEMGARDA® and Provides an Update on Next Steps with the U.S. FDA

July 06, 2026

From Invivyd

Via GlobeNewswire

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 02, 2026

From Invivyd

Via GlobeNewswire

Performance

YTD	-62.5%	-62.5%
1 Month	-8.1%	-8.1%
3 Month	-27.4%	-27.4%
6 Month	-60.6%	-60.6%
1 Year	+33.2%	+33.2%

More News

Invivyd Announces Completion of Enrollment in Phase 3 LIBERTY Trial Evaluating VYD2311 Antibody Versus mRNA COVID-19 Vaccine

June 16, 2026

From Invivyd

Via GlobeNewswire

Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge ↗

May 14, 2026

Via Chartmill

Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine

June 09, 2026

From Invivyd

Via GlobeNewswire

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 03, 2026

From Invivyd

Via GlobeNewswire

Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID

June 01, 2026

From Invivyd

Via GlobeNewswire

Invivyd to Participate in Upcoming Investor Events

May 27, 2026

From Invivyd

Via GlobeNewswire

Invivyd (IVVD) Q1 2026 Earnings Transcript ↗

May 14, 2026

Via The Motley Fool

Invivyd Q1 Earnings Call Highlights ↗

May 14, 2026

Via MarketBeat

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 14, 2026

From Invivyd

Via GlobeNewswire

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

May 11, 2026

From Invivyd

Via GlobeNewswire

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

May 07, 2026

From Invivyd

Via GlobeNewswire

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2026

From Invivyd

Via GlobeNewswire

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

April 20, 2026

From Invivyd

Via GlobeNewswire

Which stocks are experiencing notable movement on Thursday? ↗

April 09, 2026

Via Chartmill

Invivyd Announces REVOLUTION Program Progress and Advancement of Novel, Potential First- and Best-in-Class Measles Monoclonal Antibody Candidate VMS063 for Treatment and Prevention of Measles

April 09, 2026

From Invivyd

Via GlobeNewswire

Invivyd Launches “Antibodies for Any Body” in Partnership with World Champion Skier Lindsey Vonn to Inspire Actions that Help Support Immune Health

April 07, 2026

From Invivyd

Via GlobeNewswire

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 06, 2026

From Invivyd

Via GlobeNewswire

Invivyd Announces Presentation at the World Vaccine Congress Washington

March 30, 2026

From Invivyd

Via GlobeNewswire

BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

March 09, 2026

Via Benzinga

Invivyd (IVVD) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates

March 05, 2026

From Invivyd

Via GlobeNewswire

Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer

March 05, 2026

From Invivyd

Via GlobeNewswire

Invivyd to Host Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update Conference Call on March 5, 2026

March 02, 2026

From Invivyd

Via GlobeNewswire

Frequently Asked Questions

Is Invivyd, Inc. - Common Stock publicly traded?

Yes, Invivyd, Inc. - Common Stock is publicly traded.

What exchange does Invivyd, Inc. - Common Stock trade on?

Invivyd, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Invivyd, Inc. - Common Stock?

The ticker symbol for Invivyd, Inc. - Common Stock is IVVD on the Nasdaq Stock Market

What is the current price of Invivyd, Inc. - Common Stock?

The current price of Invivyd, Inc. - Common Stock is 0.9371

When was Invivyd, Inc. - Common Stock last traded?

The last trade of Invivyd, Inc. - Common Stock was at 07/08/26 10:07 AM ET

What is the market capitalization of Invivyd, Inc. - Common Stock?

The market capitalization of Invivyd, Inc. - Common Stock is 102.85M

How many shares of Invivyd, Inc. - Common Stock are outstanding?

Invivyd, Inc. - Common Stock has 103M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.